A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

Summary

This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).

Timeline

Start

2017-01-26

Primary completion

2021-03-30

Completion

2021-07-28

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo vs ABBV-8E12 300 mg; p = 0.740; Least Squares (LS) Mean of Difference 0.06 (95% CI -0.291 to 0.409) NCT02880956 ↗

Publications

• Wang D, Florian H, Lynch SY, Robieson W, Zhuang R, Kusiak C, Ross JL, Walsh JR, Graff O. Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer's disease. Alzheimers Dement (N Y). 2025 Nov 22;11(4):e70181. doi: 10.1002/trc2.70181. eCollection 2025 Oct-Dec.

Drugs

Indications